Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage...

Prior research has shown that approximately thirty percent of individuals diagnosed with metastatic castration-resistant prostate cancer (mCRPC) harbor specific genomic vulnerabilities that impair their ability to maintain chromosomal integrity. These defects primarily involve the DNA damage repair (DDR) machinery, with the Breast Cancer 2 (BRCA2) gene representing the most frequent site of alteration in this patient population. While Poly (ADP-ribose) polymerase inhibitors (PARPi) have emerged as the standard therapeutic intervention for patients possessing these molecular signatures, the utility of alternative DNA-damaging agents remains under-explored in clinical practice. Platinum-based compounds represent a class of cytotoxic drugs that induce lethal double-strand breaks by forming intra-strand crosslinks, potentially exploiting the same enzymatic deficiencies targeted by more modern inhibitors. Clinical data regarding the efficacy of these traditional agents as standalone treatments in the context of specific genetic mutations are currently sparse and often overshadowed by combination regimens. The lack of robust evidence for monotherapy complicates treatment decisions in resource-limited settings where access to newer targeted therapies is restricted. This absence of evidence motivated a rigorous evaluation of how genomic status influences the clinical trajectory of patients receiving these medications.

This investigation evaluated the clinical efficacy of single-agent platinum therapy in cohorts of patients with metastatic castration-resistant prostate cancer stratified by their DNA damage repair (DDR) status. Researchers sought to determine if specific deleterious mutations in genes such as BRCA1 or BRCA2 correlate with superior objective responses compared to non-mutated counterparts or those with other repair defects. The study aimed to quantify differences in prostate-specific antigen (PSA) decline, clinical progression-free survival, and radiographic progression-free survival across diverse genetic backgrounds. Another objective involved assessing the impact of prior exposure to Poly (ADP-ribose) polymerase inhibitors on subsequent platinum sensitivity to understand potential cross-resistance mechanisms. By comparing outcomes between DDR-positive and DDR-negative groups, the team intended to identify a subset of patients who might benefit most from this cost-effective treatment modality. The analysis focused on providing a practical therapeutic alternative for clinical settings where newer, high-cost targeted therapies are not readily accessible or approved. Ultimately, the work aimed to refine the selection criteria for platinum-based interventions in the management of advanced prostate malignancies.

This multicenter, retrospective analysis compiled clinical data from one hundred and twenty-nine individuals diagnosed with metastatic castration-resistant prostate cancer who were treated with platinum monotherapy. Participants were categorized based on the presence of deleterious germline or somatic alterations in a predefined panel of DNA damage repair genes identified through genomic sequencing. The genetic screening included the assessment of BRCA1, BRCA2, CDK12, ATM, CHEK2, PALB2, and FANCA loci to define the DDR-positive population versus the DDR-negative cohort. Clinicians monitored therapeutic success through standardized metrics, including the percentage of prostate-specific antigen (PSA) reduction and radiographic progression-free survival (PFS) as determined by imaging criteria. Overall survival (OS) was calculated from the initiation of platinum monotherapy, with specific attention paid to the influence of previous PARP inhibitor treatment on these outcomes. Statistical comparisons between the BRCA-mutated, non-BRCA DDR-positive, and DDR-negative cohorts utilized p-values to establish the significance of observed differences in treatment response and survival duration. The researchers employed a multicenter approach to ensure a diverse patient sample and increase the generalizability of the findings across different clinical environments.

Patients harboring BRCA mutations exhibited a significantly higher prostate-specific antigen (PSA) response rate of forty-eight percent compared to only thirteen percent in the DDR-negative group. Objective response rates followed a similar trend, reaching thirty-seven point five percent in the BRCA cohort while remaining near eleven percent for other DDR-positive variants. The median duration of the PSA response was five months for those with BRCA alterations, which was substantially longer than the one point seven months observed in patients without repair defects. Among individuals who had not previously received PARP inhibitors, the median overall survival reached thirteen point seven months for the BRCA-mutated group. In contrast, patients with non-BRCA DDR alterations or no detectable mutations showed shorter median survival times of eight point seven and six point one months, respectively. The data revealed that sixteen patients who had undergone prior treatment with PARP inhibitors showed no measurable response to subsequent platinum monotherapy, suggesting a potential mechanism of cross-resistance. The statistical analysis confirmed that the presence of BRCA1 or BRCA2 mutations was a strong predictor of favorable outcomes following platinum administration.

Single-agent platinum therapy shows meaningful clinical activity specifically within the subset of mCRPC patients possessing BRCA1 or BRCA2 mutations. The findings suggest that this treatment approach is most effective when used in patients who have not yet been exposed to PARP inhibitors, highlighting an optimal window for intervention. Given the significant differences in survival and response rates, genomic profiling remains an essential tool for identifying candidates for this specific pharmacological intervention in advanced prostate cancer. The broad availability and lower financial burden of platinum agents make them a viable option for healthcare systems with limited access to expensive targeted drugs. Future research should focus on optimizing the sequence of DNA-damaging therapies to maximize the duration of disease control and minimize the impact of resistance. These results provide a clear evidence base for integrating platinum monotherapy into the treatment algorithm for molecularly defined patient populations. The study underscores the importance of precision medicine in extending survival for individuals with specific genetic vulnerabilities in the DNA repair pathway.